Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX3-stratified posaconazole vs fluconazole prophylaxis in acute myeloid leukemia
2024-517211-79-00Phase 4Authorised
- Sponsor
- Lausanne University Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Invasive Mold Infections (IMIs) and 1 more comparing Posaconazole prophylaxis with Fluconazole prophylaxis (2 arms). Planned start Oct 2024; status: authorised.
02
Drugs
posaconazolefluconazole
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Invasive Mold Infections (IMIs)invasive mycoses
Beyond the preview
Go deeper on 2024-517211-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517211-79-00.